The 2026 ESMO LBA Landscape: Visualized

   
Which mechanisms are commanding the late-breaker spotlight this year?

Our analysts crunched the numbers across all LBAs:
✔️ADCs lead the field — nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond
✔️Checkpoint inhibition isn’t just a category — it’s still the default combo partner, showing up alongside ADCs, vaccines, PARP inhibitors and more
✔️Beyond PD-(L)1 and the usual ADC targets (HER2, TROP-2, B7-H3), RAS/KRAS momentum is continuing from ASCO

Stay ahead of the competitive curve with verified insights.

• #Conferences
• #ESMO

• Lung
• PARP inhibitors
• vaccines
• +14